# A Study of IBI363 in Subjects With Advanced Melanoma

Source: https://onco.cc/trials/nct06081920/  
OnCo record `nct06081920` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of IBI363 in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

A Study of IBI363 in Subjects With Advanced Melanoma is a phase 2 interventional study registered as NCT06081920 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2023-10-19 and due to reach its primary completion in 2028-10-19. Interventions recorded: IBI363. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06081920
- Phase: 2
- Setting: A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT06081920: https://clinicaltrials.gov/study/NCT06081920

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [IBI363](https://onco.cc/drugs/ibi363/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/nct06081920.json